Drugs / Risvutatug rezetecan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07268053 | Feb 2026 → Jul 2027 expected | glioblastoma, metastatic malignant neoplasm in the brain | Nader Sanai | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07602777 | Jun 2026 → Nov 2027 expected | sarcoma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07099898 | Aug 2025 → Nov 2027 expected | lung neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
Press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Risvutatug rezetecan | “In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells” NCT07099898 ↗2“The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez.” NCT07602777 ↗ |
| Known as | Ris-Rez | “In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells” NCT07099898 ↗1“The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez.” NCT07602777 ↗ |
| Route | Intravenous | “Risvutatug rezetecan will be administered intravenously.” NCT07268053 ↗ |